Madrigal Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 1/4

Madrigal Pharmaceuticals CEO'su Bill Sibold, Sep2023 tarihinde atandı, in görev süresi 1.17 yıldır. in toplam yıllık tazminatı $ 32.87M olup, şirket hissesi ve opsiyonları dahil olmak üzere 0.8% maaş ve 99.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.028% ine doğrudan sahiptir ve bu hisseler $ 2.13M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 0.9 yıl ve 8.3 yıldır.

Anahtar bilgiler

Bill Sibold

İcra Kurulu Başkanı

US$32.9m

Toplam tazminat

CEO maaş yüzdesi	0.8%
CEO görev süresi	1.2yrs
CEO sahipliği	0.03%
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	8.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Bill Sibold'un ücretlendirmesi Madrigal Pharmaceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$519m
Jun 30 2024	n/a	n/a	-US$510m
Mar 31 2024	n/a	n/a	-US$444m
Dec 31 2023	US$33m	US$275k	-US$374m

Tazminat ve Piyasa: Bill 'nin toplam tazminatı ($USD 32.87M ), UK pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 3.23M ).

Tazminat ve Kazançlar: Bill şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Bill Sibold (58 yo)

1.2yrs

Görev süresi

US$32,871,801

Tazminat

Mr. William J. Sibold, also known as Bill, serves as Chief Executive Officer, President and Director at Madrigal Pharmaceuticals, Inc. since September 8, 2023. Mr. Sibold joined Madrigal Pharmaceuticals, I...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
William Sibold	CEO, President & Director	1.2yrs	US$32.87m	0.028% $ 2.1m
Rebecca Taub	Founder	13.2yrs	US$6.93m	5% $ 378.7m
Carole Huntsman	Chief Commercial Officer	less than a year	US$3.14m	Veri yok
Mardi Dier	CFO & Senior VP	less than a year	Veri yok	Veri yok
Mark Underwood	Senior Vice President of Business Planning & Operations	less than a year	Veri yok	Veri yok
Ronald Filippo	Chief Information Officer	less than a year	Veri yok	Veri yok
Tina Ventura	Chief Investor Relations Officer	less than a year	Veri yok	Veri yok
Shannon Kelley	Chief Compliance Office & General Counsel	less than a year	Veri yok	Veri yok
Clint Wallace	Chief Human Resources Officer	less than a year	Veri yok	Veri yok
Edward Chiang	Senior Vice President of Clinical & Technical Operations	no data	Veri yok	Veri yok
Thomas Hare	Senior Vice President of Clinical Management	no data	Veri yok	Veri yok
Robert Waltermire	Chief Pharmaceutical Development Officer	3.3yrs	Veri yok	0.025% $ 1.9m

0.9yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim: 0JXI 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.9 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
William Sibold	CEO, President & Director	1.2yrs	US$32.87m	0.028% $ 2.1m
Rebecca Taub	Founder	8.3yrs	US$6.93m	5% $ 378.7m
Frederick Craves	Independent Lead Director	8.3yrs	US$65.00k	1.7% $ 128.8m
Kenneth Bate	Independent Director	8.3yrs	US$77.50k	0.0055% $ 416.0k
Julian Baker	Independent Chairman of the Board	1.4yrs	US$33.75k	0.011% $ 832.8k
Paul Friedman	Director	8.3yrs	US$9.80m	4.35% $ 329.6m
Richard Levy	Independent Director	8.3yrs	US$62.50k	0.047% $ 3.6m
James Daly	Independent Director	5.4yrs	US$57.50k	0.0055% $ 416.0k
Raymond Cheong	Independent Director	1.4yrs	US$27.50k	0.011% $ 832.8k

8.3yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 0JXI 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.3 yıldır).

Madrigal Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Madrigal Pharmaceuticals, Inc. Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development

CEO, President & Director recently sold US$1.6m worth of stock

Madrigal Pharmaceuticals, Inc. Appoints Shannon Kelley as General Counsel

Madrigal Pharmaceuticals, Inc., Annual General Meeting, Jun 25, 2024

Madrigal Pharmaceuticals, Inc. Announces Management Changes

Madrigal Pharmaceuticals, Inc. Appoints CFO Changes

Recent updates

Madrigal Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Forecast to breakeven in 2026

Madrigal Pharmaceuticals, Inc. Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development

CEO, President & Director recently sold US$1.6m worth of stock

Madrigal Pharmaceuticals, Inc. Appoints Shannon Kelley as General Counsel

Madrigal Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Madrigal Pharmaceuticals, Inc. Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra (resmetirom) Presented at the EASL Congress

No longer forecast to breakeven

Madrigal Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Madrigal Pharmaceuticals, Inc., Annual General Meeting, Jun 25, 2024

Madrigal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

Madrigal Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $599.999764 million.

Madrigal Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $599.999764 million.

Madrigal Pharmaceuticals, Inc. Announces FDA Approval of Rezdiffra™ (Resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (Nash) with Moderate to Advanced Liver Fibrosis

Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis

Forecast breakeven date moved forward to 2025

Madrigal Pharmaceuticals, Inc. Announces Management Changes

Madrigal Pharmaceuticals, Inc. Appoints CFO Changes

Forecast breakeven date pushed back to 2026

New major risk - Financial position

Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

New major risk - Share price stability

Madrigal Pharmaceuticals, Inc. Announces Additions to its Leadership Team

Madrigal Pharmaceuticals, Inc. Appoints Ronald Filippo as Chief Information Officer

Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer

New major risk - Financial position

Madrigal Pharmaceuticals, Inc. Announces the Resignation of Remy Sukhija as Chief Commercial Officer

Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of Nash with Liver

Madrigal Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Madrigal Pharmaceuticals, Inc. Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

Madrigal Pharmaceuticals, Inc. Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of Nash with Liver Fibrosis

Forecast to breakeven in 2025

Madrigal Pharmaceuticals, Inc. announced that it has received $90 million in funding

Madrigal Pharmaceuticals, Inc. Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis

Insufficient new directors

Insufficient new directors

Insufficient new directors

Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis

Insufficient new directors

Madrigal Pharmaceuticals, Inc. Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™

Insufficient new directors

Madrigal Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Insufficient new directors

Madrigal Pharmaceuticals Provides Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results

Insufficient new directors

Madrigal Pharmaceuticals, Inc. Announces Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health

Madrigal Pharmaceuticals to Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom

Insufficient new directors

Insufficient new directors

Madrigal Pharmaceuticals, Inc. Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom

Insufficient new directors

Insufficient new directors

Madrigal Pharmaceuticals, Inc. Offers Patients Resmetirom in Open Label Active Treatment Extension of the Phase 3 MAESTRO-NAFLD-1 Clinical Study

Madrigal Pharmaceuticals Completes Enrollment of the 52 Week Liver Biopsy Patient Population in the Phase 3 MAESTRO-NASH Study of Resmetirom

Madrigal Pharmaceuticals Announces Presentation of Positive Clinical Data of Resmetirom from Open-Label Portion of Ongoing Phase 3 Clinical Trial Maestro-Nafld-1

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş